Current overview of the management of urogenital atrophy in women with breast cancer

Breast Journal

Volumn 17, Issue 4, 2011, Pages 403-408

  Pruthi, Sandhya ^a   Simon, James A ^b   Early, Amy P ^c  

^a MAYO CLINIC   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

breast cancer; vaginal estrogen; vulvovaginal atrophy

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRADIOL ACETATE; ESTROGEN; FULVESTRANT; GABAPENTIN; K-Y JELLY; LETROZOLE; LIDOCAINE; LUBRICATING AGENT; PLANT EXTRACT; POLYCARBOPHIL; TAMOXIFEN; TESTOSTERONE; UNCLASSIFIED DRUG; ZESTRA;

BREAST CANCER; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVOR; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); CREAM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; GEL; HUMAN; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MEDICAL HISTORY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYMPTOMATOLOGY; TABLET; UROGENITAL ATROPHY; UROGENITAL TRACT DISEASE; VAGINA ATROPHY; VAGINA DISEASE; VAGINA RING; VULVOVAGINAL DISEASE;

ADMINISTRATION, INTRAVAGINAL; ATROPHY; BREAST NEOPLASMS; ESTRADIOL; FEMALE; HUMANS; SEXUAL BEHAVIOR; TESTOSTERONE; UROGENITAL SYSTEM;

EID: 79960428256     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2011.01089.x     Document Type: Review

References (45)

1. Ganz PA, Rowland JH, Desmond K, et al. Life after breast cancer: understanding women's health-related quality of life and sexual functioning. J Clin Oncol 1998; 16: 501-14. (Pubitemid 28135592)
2. Cella D, Fallowfield L, Barker P, Cuzick J, Locher G, Howell A, ATAC Trialists 9 Group. Quality of life of postmenopausal women in the ATAC ("Arimidex," Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006; 100: 273-84. (Pubitemid 44707921)
3. Ponzone R, Biglia N, Jacomuzzi MF, et al. Vaginal oestrogen therapy after breast cancer: is it safe? European J Cancer 2005; 41: 2673-81. (Pubitemid 41607558)
4. Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer. Anticancer Drugs 2004; 15: 753-60. (Pubitemid 39281298)
5. Ibe C, Simon JA,. Vulvovaginal atrophy: current and future therapies. J Sex Med 2010; 7: 1042-50.
6. Smith IA, Dowsett M,. Aromatase inhibitors in breast cancer. N Engl J Med 2003; 348: 2431-42. (Pubitemid 36682823)
7. Fallowfield L, Cella D, Cizick J, Francis S, et al. Quality of life of postmenopausal women in the "Arimidex," Tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004; 22: 4261-71. (Pubitemid 41185147)
8. National Comprehensive Cancer Network Clinical Practice Guidelines, Version 2. Breast Cancer. Available at: (accessed December 16, 2010).
9. Robertson JFR, Osborne K, Howell A, Jones SE, et al. Fulvestrant versus anastrazole for the treatment of advanced breast carcinoma in postmenopausal women. A prospective analysis of two multicenter trials. Cancer 2003; 98: 229-38. (Pubitemid 36828445)
10. Wiegernik MA, Poortman J, Agema AR, Thhijssen JH,. Estrogen receptors in human vaginal tissue. Maturitas 1980; 2: 59-67. (Pubitemid 10127607)
11. Losif CS, Batra S, Ek A, et al. Estrogen receptors in the female urinary tract. Am J Obstet Gynecol 1981; 141: 817-20.
12. Elia G, Bergman A,. Estrogen effects of the urethra: Beneficial effects in women with genuine stress incontinence. Obstet Gynecol Surv 1993; 48: 509-15.
13. Castelo-Branco C, Cancelo MJ, Vilero J, et al. Management of postmenopausal vaginal atrophy and atrophic vaginitia. Matruitas 2005; 52 (Suppl 1): S46-52. (Pubitemid 41630619)
14. Bruno D, Geeney KJ,. Management of postmenopausal symptoms in breast cancer survivors. Semin Oncol 2006; 33: 695-707.
15. Chelbowski RT, Anderson GL, Mass M, et al. for the WHI Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010; 304: 1684-92.
16. Beral V, The Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27. (Pubitemid 36999703)
17. Col NF, Kim JA, Chlebowski RT,. Menopausal hormone replacement therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res 2005; 7: R535-40.
18. Pritchard KI, Khan H, Levine M,. Clinical practice guideline for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. CMAJ 2002; 166: 1017-22. (Pubitemid 34304644)
19. Society of Obstetricians and Gynaecologists of Canada. Use of hormonal replacement therapy after treatment of breast cancer. Number 142, May 2004. Int J Gynaecol Obstet 2005; 88: 216-21.
20. Holberg L, Andersson H,. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomized comparison: trial stopped. Lancet 2004; 363: 453-5.
21. Von Schoultz E, Rutquist LE, on Behalf of the Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005; 97: 533-5
22. Suckling J, Lethaby A, Kennedy R,. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2003; 4: CD001500.
23. Labrie F, Archer D, Bouchard C, et al. Serum steroid levels during 12-week intravaginal dehydroepiandosterone administration. Menopause 2009; 16: 897-906.
24. Nilsson K, Heimer G,. Low-dose estradiol in the treatment of urogenital estrogen deficiency - a pharmacologic and phamacodynamic study. Maturitas 1992; 15: 121-7.
25. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M,. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis; a randomized controlled trial. Obstet Gynecol 2008; 111: 67-76.
26. Eugster-Mausmann M, Waitzinger J, Lehnick D,. Minimized estradiol absorption with ultra-low dose 10 mcg 17 β-estradiol vaginal tablets. Climacteric 2010; 13: 219-27.
27. Simon J, Nachitgall L, Ulrich L, et al. Endometrial safety of ultra-low dose estradiol vaginal tablets. Obstet Gynecol 2010; 116: 876-83.
28. Wang S, Paris F, Sultan CS, et al. Recombinant cell ultrasensitive bioassay for measurement of estrogens in postmenopausal women. J Clin Endocrinol Metab 2005; 90: 1407-13. (Pubitemid 40463996)
29. Kendall A, Dowsett M, Folkerd E, Smith I,. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 2006; 17: 584-7.
30. Memorial Sloan-Kettering Cancer Center Clinical Trial. Serum estradiol levels in postemenopausal women with breast cancer receiving adjuvant aromatase inhibitors and vaginal estrogen. NCT00984300. Available at: http://www. ClinicalTrials.gov (accessed September 26, 2010).
31. Dimitrakakis C, et al. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormonal therapy. Menopause 2004; 11: 531-3.
32. Hofling M, Hirschberg AL, Skoog L, Tani E, Hägerström T, Von Schoultz B,. Testosterone inhibits estrogen/progestin-induced breast cell proliferation in postmenopausal women. Menopause 2007; 14: 183-89.
33. von Schoultz B,. Androgens and the breast. Maturitas 2007; 57: 47-9.
34. Derzko C, Elliott S, Lam W,. Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy. Curr Oncol 2007; 14 (Suppl 1): S20-40.
35. Witherby SM, Johnson JV, O'Brien P, Demers LM, Mount SL, Muss HB,. Efficacy and safety of topical testosterone for atrophic vaginitis in breast cancer patients on aromatase inhibitors: a pilot study. Breast Cancer Res Treat 2007; 106 (Suppl): S276. Abstract 6086
36. Vaginal Testosterone Cream for Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer. NCT01122342. Available at: http://www.ClinicalTrials.gov (accessed December 17, 2010).
37. Labrie F, et al. Effect of intravaginal dehydroepiandrosterone (prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009; 16: 923-31.
38. Trinkaus M, Shin S, Wolfman W, Simmons C, Clemons M,. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008; 13: 222-31. (Pubitemid 351679897)
39. Wiggins DL, Dizon D,. Dyspareunia and vaginal dryness after breast cancer treatment. SRM 2008; 6: 19-22. Available at: http://www.srm-ejournal.com (accessed September 26, 2010).
40. Kalogeraki A, Tamiolakis D, Relakis K, et al. Cigarette smoking and vaginal atrophy in postmenopausal women. In Vivo 1996; 10: 597-600. (Pubitemid 27023169)
41. Leiblum S, Bachmann G, Kemmann E, et al. Vaginal atrophy in the post-menopausal woman; the importance of sexual activity and hormones. JAMA 1983; 249: 2195-8. (Pubitemid 13118676)
42. Byderman M, Swahn ML,. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 1996; 23: 259-63. (Pubitemid 26000605)
43. Loprinzi CL, Abu-Ghazelah S, Sloan JA, et al. Phase II randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 1997; 15: 969-73. (Pubitemid 27106279)
44. Le Veque FG, Hendrix S,. Oral pilocarpine to treat vaginal xerosis associated with chemotherapy-induced amenorrhea in premenopausal women. J Clin Oncol 2004; 22 (Suppl):145. Abstract 8099.
45. Ferguron DM, Steidle CP, Singh GS, et al. Randomized, placebo-controlled, double-blind, crossover design trial of the efficacy and safety of Zestra for Women in women with and without female sexual arousal disorder. J Sex Marital Ther 2003; 29 (Suppl): 33-44. (Pubitemid 36070978)